Group IIA phospholipase A2 as a prognostic marker in prostate cancer: Relevance to clinicopathological variables and disease-specific mortality

APMIS

Volumn 117, Issue 3, 2009, Pages 151-161

  Mirtti, Tuomas ^a,b   Laine, Veli Jukka O ^b   Hiekkanen, Heikki ^b   Hurme, Saija ^b   Rowe, Outi ^c   Nevalainen, Timo J ^b   Kallajoki, Markku ^b   Alanen, Kalle ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c BUPA Hospitals   (United Kingdom)

Author keywords

Cancer; Phospholipase A2; Prognosis; Prostate

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; KI 67 ANTIGEN; MESSENGER RNA; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP IIA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY;

AGED; CARCINOMA; DISEASE PROGRESSION; GROUP II PHOSPHOLIPASES A2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; RETROSPECTIVE STUDIES; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 61349123574     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.00002.x     Document Type: Article

References (41)

1. Six DA, Dennis EA. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 2000 1488 : 1 19.
2. Chaudry A, McClinton S, Moffat LE, Wahle KW. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 1991 64 : 1157 60.
3. Chaudry AA, Wahle KW, McClinton S, Moffat LE. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994 57 : 176 80.
4. Levine L. Arachidonic acid transformation and tumor production. Adv Cancer Res 1981 35 : 49 79.
5. Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 2003 169 : 2352 9.
6. Catalano A, Procopio A. New aspects on the role of lipoxygenases in cancer progression. Histol Histopathol 2005 20 : 969 75.
7. Rose DP, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 1991 18 : 243 54.
8. Liu B, Maher RJ, Hannun YA, Porter AT, Honn KV. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. J Natl Cancer Inst 1994 86 : 1145 51.
9. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998 95 : 681 6.
10. Nevalainen TJ, Haapamäki MM, Grönroos JM. Roles of secretory phospholipases A(2) in inflammatory diseases and trauma. Biochim Biophys Acta 2000 1488 : 83 90.
11. Laine VJ, Grass DS, Nevalainen TJ. Protection by group II phospholipase A2 against Staphylococcus aureus. J Immunol 1999 162 : 7402 8.
12. Koduri RS, Grönroos JO, Laine VJ, Le Calvez C, Lambeau G, Nevalainen TJ, et al. Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A(2). J Biol Chem 2002 277 : 5849 57.
13. Grönroos JO, Laine VJ, Janssen MJ, Egmond MR, Nevalainen TJ. Bactericidal properties of group IIA and group V phospholipases A2. J Immunol 2001 166 : 4029 34.
14. Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, Ji J, et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A 2002 99 : 16203 8.
15. Yamashita S, Yamashita J, Ogawa M. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 1994 69 : 1166 70.
16. Ying Z, Tojo H, Komatsubara T, Nakagawa M, Inada M, Kawata S, et al. Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma. Biochim Biophys Acta 1994 1226 : 201 5.
17. Nevalainen TJ, Haapanen TJ. Distribution of pancreatic (group I) and synovial-type (group II) phospholipases A2 in human tissues. Inflammation 1993 17 : 453 64.
18. Kallajoki M, Alanen KA, Nevalainen M, Nevalainen TJ. Group II phospholipase A2 in human male reproductive organs and genital tumors. Prostate 1998 35 : 263 72.
19. Graff JR, Konicek BW, Deddens JA, Chedid M, Hurst BM, Colligan B, et al. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 2001 7 : 3857 61.
20. Jiang J, Neubauer BL, Graff JR, Chedid M, Thomas JE, Roehm NW, et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 2002 160 : 667 71.
21. Faas FH, Dang AQ, Pollard M, Hong XM, Fan K, Luckert PH, et al. Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J Urol 1996 156 : 243 8.
22. Sved P, Scott KF, McLeod D, King NJ, Singh J, Tsatralis T, et al. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res 2004 64 : 6934 40.
23. Dong Q, Patel M, Scott KF, Graham GG, Russell PJ, Sved P. Oncogenic action of phospholipase A(2) in prostate cancer. Cancer Lett 2006 240 : 9 16.
24. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000 60 : 4629 37.
25. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon : IARC Press, 2004.
26. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966 50 : 125 8.
27. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002 62 : 2220 6.
28. Nevalainen TJ, Haapanen TJ, Rajala P, Ekfors T. Expression of group II phospholipase A2 in Paneth cells of an adenoma of the rectum. A case report. APMIS 1998 106 : 780 4.
29. Di Marco S, Marki F, Hofstetter H, Schmitz A, van Oostrum J, Grutter MG. Purification, analysis, and enzymatic activity of recombinant human synovial fluid phospholipase A2 and N-terminal variants. J Biochem (Tokyo) 1992 112 : 350 4.
30. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002 26 : 312 9.
31. Mostofi FK. Grading of prostatic carcinoma. Cancer Chemother Rep 1975 59 : 111 7.
32. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001 412 : 822 6.
33. Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Y Anazawa, et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 2004 64 : 5963 72.
34. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995 81 : 957 66.
35. Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997 17 : 88 91.
36. Ilsley JN, Nakanishi M, Flynn C, Belinsky GS, De Guise S, Adib JN, et al. Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res 2005 65 : 2636 43.
37. Ferdinandusse S, Denis S, Ijlst L, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 2000 41 : 1890 6.
38. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993 85 : 1571 9.
39. Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, et al. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol 2004 164 : 787 93.
40. Mobley JA, Leav I, Zielie P, Wotkowitz C, Evans J, Lam YW, et al. Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro. Cancer Epidemiol Biomarkers Prev 2003 12 : 775 83.
41. Kashiwagi M, Friess H, Uhl W, Berberat P, Abou-Shady M, Martignoni M, et al. Group II and IV phospholipase A(2) are produced in human pancreatic cancer cells and influence prognosis. Gut 1999 45 : 605 12.